Sanofi's Rilzabrutinib Fails At First Hurdle In Pemphigus Study
BTK Inhibitor Came With Principia Purchase
Analysts who felt Sanofi paid way over the odds when splashing out $3.7bn to buy Principia last year will be feeling justified in that stance after one of the oral BTK inhibitors acquired, rilzabrutinib, proved to be no more effective than placebo in a Phase III trial.
